Rabbit EPM2A Polyclonal Antibody | anti-EPM2A antibody

EPM2A Polyclonal Antibody

Cat. Num. AAA2562573

• Gene Names: EPM2A; EPM2; MELF
• Reactivity: Human, Mouse, Rat
• Applications: Immunohistochemistry, ELISA
• Purity: Antigen Affinity Purification
• Synonyms: EPM2A; Polyclonal Antibody; EPM2A Polyclonal Antibody; Epilepsy progressive myoclonus type 2 Lafora disease (laforin); Epilepsy progressive myoclonus type 2A Lafora disease (laforin); EPM2; Epm2a; Epm2a gene; Lafora PTPase; Laforin; LAFPTPase; LD; LDE; MELF; RP3-466P17.2; anti-EPM2A antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Antigen Affinity Purification
• Form/Format: PBS with 0.05% NaN3 and 40% Glycerol, pH7.4
• Concentration: 1.32mg/mL (varies by lot)
• Sequence Length: 331

• Applicable Applications for anti-EPM2A antibody: Immunohistochemistry (IHC), ELISA (EIA)
• Application Notes: IHC: 1:50-1:300; ELISA: 1:5000-1:10000
• Immunogen: Fusion protein of human EPM2A
• Conjugation: Unconjugated
• Preparation and Storage: Store at -20 degree C. Avoid freeze/thaw cycles.

Immunohistochemistry (IHC)

(Immunohistochemistry of paraffin-embedded Human cervical cancer tissue using EPM2A Polyclonal Antibody at dilution of 1:75(×200))

Immunohistochemistry (IHC)

(Immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using EPM2A Polyclonal Antibody at dilution of 1:75(×200))

Related Product Information for anti-EPM2A antibody

This gene encodes a dual-specificity phosphatase that associates with polyribosomes. The encoded protein may be involved in the regulation of glycogen metabolism. Mutations in this gene have been associated with myoclonic epilepsy of Lafora. Alternative splicing results in multiple transcript variants. 

Product Categories/Family for anti-EPM2A antibody

Metabolism; Signal Transduction

NCBI and Uniprot Product Information

• NCBI GI #: 11321613
• NCBI GeneID: 7957
• NCBI Accession #: NP_005661; BC005286
• NCBI GenBank Nucleotide #: NP_005661.1
• UniProt Accession #: O95278; B3EWF7
• NCBI Official Full Name: laforin isoform a
• NCBI Official Synonym Full Names: EPM2A glucan phosphatase, laforin
• NCBI Official Symbol: EPM2A
• NCBI Official Synonym Symbols: EPM2; MELF
• NCBI Protein Information: laforin
• UniProt Protein Name: Laforin
• Protein Family: EPM2A-interacting protein
• UniProt Gene Name: EPM2A
• UniProt Synonym Gene Names: LAFPTPase
• UniProt Entry Name: EPM2A_HUMAN

NCBI Description

This gene encodes a dual-specificity phosphatase and may be involved in the regulation of glycogen metabolism. The protein acts on complex carbohydrates to prevent glycogen hyperphosphorylation, thus avoiding the formation of insoluble aggregates. Loss-of-function mutations in this gene have been associated with Lafora disease, a rare, adult-onset recessive neurodegenerative disease, which results in myoclonus epilepsy and usually results in death several years after the onset of symptoms. The disease is characterized by the accumulation of insoluble particles called Lafora bodies, which are derived from glycogen. [provided by RefSeq, Jan 2018]

Uniprot Description

laforin: Dual specificity protein phosphatase. May be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules (polyglucosans). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Forms a complex with NHLRC1/malin and HSP70 and this complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2 (EPM2); also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. EPM2 occurs worldwide, but it is particularly common in the mediterranean countries of southern Europe and northern Africa, in southern India and in the Middle East. At the cellular level, it is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle. Among other conditions involving polyglucosans, EPM2 is unique in that the inclusions are in neuronal dendrites but not axons and the forming polyglucosan fibrils are associated with the endoplasmic reticulum. Belongs to the protein-tyrosine phosphatase family. 9 isoforms of the human protein are produced by alternative splicing.

Protein type: Protein phosphatase, dual-specificity; EC 3.1.3.48; EC 3.1.3.16; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 6q24

Cellular Component: polysome; endoplasmic reticulum; cytoplasm; plasma membrane; cytosol; nucleus

Molecular Function: protein binding; phosphoinositide 5-phosphatase activity; protein tyrosine/serine/threonine phosphatase activity; carbohydrate phosphatase activity; protein tyrosine phosphatase activity; protein serine/threonine phosphatase activity

Biological Process: glycogen metabolic process; nervous system development; habituation; glycogen biosynthetic process; inositol phosphate dephosphorylation; carbohydrate metabolic process; glucose metabolic process; autophagy; pathogenesis; protein amino acid dephosphorylation

Disease: Myoclonic Epilepsy Of Lafora